Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares de Souza M, de Souza GA, Fidalgo TM, Arajo AC, de Souza Gonzaga HF, de Bortoli Teixeira D, de Oliveira Silva Ullmann T, Sloan KP, Sloan LA (2022) GLP-1a: Going beyond Traditional Use
What to monitor: Nausea severity and duration after each injection
doi: 10.3892/etm.2020.8714 12
[42] [43] Contraindications [edit] Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or in people with multiple endocrine neoplasia type 2
Cell 6:331343
It doesn't mean the active ingredient itself is unresearched - semaglutide and tirzepatide as active pharmaceutical ingredients have extensive clinical evidence bases